Search Results - "Konner, Jason"

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study by Matulonis, Ursula A, Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A, Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G, Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L

“…Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab…”
Get full text

Epigenetic Therapy in a Rare Ovarian Cancer — A Double-Edged Sword by Hsu, Charles, Konner, Jason A., Gounder, Mrinal M.

“…A woman with a rare ovarian tumor driven by EZH2 activity responded to tazemetostat, an EZH2 inhibitor, but T-cell acute lymphoblastic leukemia later developed…”
Get full text

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study by Moore, Kathleen N, Martin, Lainie P, O'Malley, David M, Matulonis, Ursula A, Konner, Jason A, Perez, Raymond P, Bauer, Todd M, Ruiz-Soto, Rodrigo, Birrer, Michael J

“…Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate…”
Get full text

Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study by Zivanovic, Oliver, Chi, Dennis S, Zhou, Qin, Iasonos, Alexia, Konner, Jason A, Makker, Vicky, Grisham, Rachel N, Brown, Amy K, Nerenstone, Stacy, Diaz, John P, Schroeder, Eric D, Langstraat, Carrie L, Paroder, Viktoriya, Lakhman, Yulia, Soldan, Krysten, Su, Katy, Gardner, Ginger J, Andikyan, Vaagn, Guo, Jianxia, Jewell, Elizabeth L, Long Roche, Kara, Troso-Sandoval, Tiffany, Lichtman, Stuart M, Moukarzel, Lea A, Dessources, Kimberly, Abu-Rustum, Nadeem R, Aghajanian, Carol, Tew, William P, Beumer, Jan, Sonoda, Yukio, O'Cearbhaill, Roisin E

“…The purpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during…”
Get full text

Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series by Sia, Tiffany Y, Manning-Geist, Beryl, Gordhandas, Sushmita, Murali, Rajmohan, Marra, Antonio, Liu, Ying L, Friedman, Claire F, Hollmann, Travis J, Zivanovic, Oliver, Chi, Dennis S, Weigelt, Britta, Konner, Jason A, Zamarin, Dmitriy

“…Although immune checkpoint blockade has demonstrated limited effectiveness against ovarian cancer, subset analyses from completed trials suggest possible…”
Get more information

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer by Weigelt, Britta, Comino-Méndez, Iñaki, de Bruijn, Ino, Tian, Lei, Meisel, Jane L, García-Murillas, Isaac, Fribbens, Charlotte, Cutts, Ros, Martelotto, Luciano G, Ng, Charlotte K Y, Lim, Raymond S, Selenica, Pier, Piscuoglio, Salvatore, Aghajanian, Carol, Norton, Larry, Murali, Rajmohan, Hyman, David M, Borsu, Laetitia, Arcila, Maria E, Konner, Jason, Reis-Filho, Jorge S, Greenberg, Roger A, Robson, Mark E, Turner, Nicholas C

“…Resistance to platinum-based chemotherapy or PARP inhibition in germline or mutation carriers may occur through somatic reversion mutations or intragenic…”
Get full text

Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases by da Silva, Edaise M., Fix, Daniel J., Sebastiao, Ana Paula Martins, Selenica, Pier, Ferrando, Lorenzo, Kim, Sarah H., Stylianou, Anthe, Da Cruz Paula, Arnaud, Pareja, Fresia, Smith, Evan S., Zehir, Ahmet, Konner, Jason A., Cadoo, Karen, Reis-Filho, Jorge S., Abu-Rustum, Nadeem R., Mueller, Jennifer J., Weigelt, Britta, Park, Kay J.

“…Mesonephric carcinoma of the cervix is a rare tumor derived from Wolffian remnants. Mesonephric-like carcinomas of the ovary and endometrium, while…”
Get full text

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine by Martin, Lainie P., Konner, Jason A., Moore, Kathleen N., Seward, Shelly M., Matulonis, Ursula A., Perez, Raymond P., Su, Ying, Berkenblit, Anna, Ruiz-Soto, Rodrigo, Birrer, Michael J.

“…To characterize folate receptor alpha (FRα) expression in archival and fresh biopsy tumor samples from relapsed ovarian cancer patients. Patients with ovarian…”
Get full text

Ovarian clear cell carcinoma, outcomes by stage: The MSK experience by Shu, Catherine A, Zhou, Qin, Jotwani, Anjali R, Iasonos, Alexia, Leitao, Mario M, Konner, Jason A, Aghajanian, Carol A

“…Abstract Objective Ovarian clear cell carcinomas (OCCCs) are rare, and uncertainty exists as to the optimal treatment paradigm and validity of the FIGO staging…”
Get full text

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer by Moore, Kathleen N, Martin, Lainie P, O'Malley, David M, Matulonis, Ursula A, Konner, Jason A, Vergote, Ignace, Ponte, Jose F, Birrer, Michael J

“…Resistance to platinum-based therapy poses a significant clinical challenge for the management of advanced ovarian cancer, a leading cause of cancer mortality…”
Get full text

Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients by Sabbatini, Paul, Tsuji, Takemasa, Ferran, Luis, Ritter, Erika, Sedrak, Christine, Tuballes, Kevin, Jungbluth, Achim A, Ritter, Gerd, Aghajanian, Carol, Bell-McGuinn, Katherine, Hensley, Martee L, Konner, Jason, Tew, William, Spriggs, David R, Hoffman, Eric W, Venhaus, Ralph, Pan, Linda, Salazar, Andres M, Diefenbach, Catherine Magid, Old, Lloyd J, Gnjatic, Sacha

“…Long peptides are efficiently presented to both CD4(+) and CD8(+) T cells after intracellular processing by antigen-presenting cells. To investigate the safety…”
Get full text

Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial by Gupta, Aditi, O'Cearbhaill, Roisin E., Block, Matthew S., Hamilton, Erika, Konner, Jason A., Knutson, Keith L., Potts, James, Garrett, Gerald, Kenney, Richard T., Wenham, Robert M.

“…Folate receptor alpha (FRα) is overexpressed on >90% of high-grade epithelial ovarian cancers (EOC). Targeting FRα with antibody-drug conjugates has proven…”
Get full text

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine by Matulonis, Ursula A, Birrer, Michael J, O'Malley, David M, Moore, Kathleen N, Konner, Jason, Gilbert, Lucy, Martin, Lainie P, Bauer, Todd M, Oza, Amit M, Malek, Karim, Pinkas, Jan, Kim, Stella K

“…Reversible, low-grade ocular adverse events (AE) are associated with administration of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeted…”
Get full text

Reply to Z.R. McCaw et al by Matulonis, Ursula A., Lorusso, Domenica, Oaknin, Ana, Pignata, Sandro, Dean, Andrew, Denys, Hannelore, Colombo, Nicoletta, Van Gorp, Toon, Konner, Jason A., Marin, Margarita Romeo, Harter, Philipp, Murphy, Conleth G., Wang, Jiuzhou, Noble, Elizabeth, Esteves, Brooke, Method, Michael, Coleman, Robert L.

Get full text

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer by Friedman, Claire F, Snyder Charen, Alexandra, Zhou, Qin, Carducci, Michael A, Buckley De Meritens, Alexandre, Corr, Bradley R, Fu, Siqing, Hollmann, Travis J, Iasonos, Alexia, Konner, Jason A, Konstantinopoulos, Panagiotis A, Modesitt, Susan C, Sharon, Elad, Aghajanian, Carol, Zamarin, Dmitriy

“…There are limited treatment options for patients with metastatic or recurrent cervical cancer. Platinum-based chemotherapy plus the anti-vascular endothelial…”
Get full text

Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer by Liu, Ying L., Zhou, Qin, Iasonos, Alexia, Emengo, Vivian N., Friedman, Claire, Konner, Jason A., O'Cearbhaill, Roisin E., Aghajanian, Carol, Zamarin, Dmitriy

“…Immune checkpoint inhibitors (ICIs) have modest activity in ovarian cancer (OC), yet little is known about their effects on subsequent treatment. Preclinical…”
Get full text

Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma by Movva, Sujana, Seier, Kenneth, Avutu, Viswatej, Banks, Lauren B, Chan, Jason, Chi, Ping, Dickson, Mark A, Gounder, Mrinal M, Kelly, Ciara M, Keohan, Mary L, Maki, Robert, Rosenbaum, Evan, Salcito, Tiffany, Rodriguez, Kaithleen, Dempsey, Rebecca, Meyers, Paul A, Cohen, Seth M, Hensley, Martee L, Konner, Jason A, Schram, Alison M, Lefkowitz, Robert A, Erinjeri, Joseph P, Qin, Li-Xuan, Tap, William D, D'Angelo, Sandra P

“…Survival of patients with metastatic sarcoma remains poor, and there is pressing need for new therapies. Most sarcoma subtypes are not responsive to immune…”
Get full text

Genetic predisposition to bevacizumab-induced hypertension by Frey, Melissa K., Dao, Fanny, Olvera, Narciso, Konner, Jason A., Dickler, Maura N., Levine, Douglas A.

“…Bevacizumab, a monoclonal antibody to VEGF, has shown efficacy in ovarian, cervical and endometrial cancer in addition to several other solid tumors. Serious…”
Get full text

Refractive Shifts and Changes in Corneal Curvature Associated With Antibody–Drug Conjugates by Canestraro, Julia, Hultcrantz, Malin, Modi, Shanu, Hamlin, Paul A., Shoushtari, Alexander N., Konner, Jason A., Tew, William P., Iyengar, Neil M., Heinemann, Murk, Abramson, David H., Francis, Jasmine H.

“…Antibody-drug conjugates (ADCs) are a class of cancer drug wherein some are associated with corneal abnormalities, but there is a dearth of published…”
Get full text

Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study by KONNER, Jason A, BELL-MCGUINN, Katherine M, LARSON, Steven M, OLD, Lloyd J, SABBATINI, Paul, HENSLEY, Martee L, TEW, William P, PANDIT-TASKAR, Neeta, VANDER ELS, Nicholas, PHILLIPS, Martin D, SCHWEIZER, Charles, WEIL, Susan C

“…Folate receptor α expression is highly restricted in normal adult tissues but upregulated in a wide range of human cancer types, including epithelial ovarian…”
Get full text